Alumis Inc

Industry · 13 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Mod Hepatic Impairment	Phase 1	2025-04-29
Completed	An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Mod Renal Impairment	Phase 1	2025-04-23
Active Not Recruiting	Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Plaque Psoriasis, Psoriasis (PsO), Psoriasis	Phase 3	2025-01-08
Completed	A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Plaque Psoriasis	Phase 3	2024-08-20
Completed	A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Plaque Psoriasis	Phase 3	2024-07-25
Completed	An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 Healthy Volunteer	Phase 1	2024-06-21
Completed	An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-0 Healthy Volunteer	Phase 1	2024-04-22
Active Not Recruiting	Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythem SLE	Phase 2	2023-06-26
Terminated	POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or P Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis	Phase 2	2023-06-14
Active Not Recruiting	Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis Plaque Psoriasis	Phase 2	2023-01-17
Completed	A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Plaque Psoriasis	Phase 2	2022-09-27
Completed	Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants Safety and Tolerability	Phase 1	2022-05-12
Completed	Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants Pharmacokinetics	Phase 1	2022-03-17